Frontiers in Pharmacology,
Journal Year:
2024,
Volume and Issue:
15
Published: Jan. 31, 2024
Cuproptosis
is
a
recently
discovered
form
of
cell
death
that
mediated
by
copper
(Cu)
and
non-apoptotic
related
to
oligomerization
lipoylated
proteins
loss
Fe-S
protein
clusters.
Since
its
discovery,
cuproptosis
has
been
extensively
studied
researchers
for
mechanism
potential
applications
in
the
treatment
cancer.
Therefore,
this
article
reviews
specific
currently
studied,
as
well
principles
strategies
use
anti-cancer
treatment,
with
aim
providing
reference
cuproptosis-based
cancer
therapy.
Journal of Materials Chemistry B,
Journal Year:
2022,
Volume and Issue:
10(33), P. 6296 - 6306
Published: Jan. 1, 2022
A
copper
nanomedicine
shows
the
glutathione-resistant
anticancer
effect
and
reverses
cisplatin
chemotherapy
resistance
in
non-small-cell
lung
cancer
by
cuproptosis.
Drug Resistance Updates,
Journal Year:
2023,
Volume and Issue:
72, P. 101018 - 101018
Published: Nov. 11, 2023
Cuproptosis
is
a
newly
identified
form
of
cell
death
driven
by
copper.
Recently,
the
role
copper
and
triggered
in
pathogenesis
cancers
have
attracted
attentions.
has
garnered
enormous
interest
cancer
research
communities
because
its
great
potential
for
therapy.
Copper-based
treatment
exerts
an
inhibiting
tumor
growth
may
open
door
chemotherapy-insensitive
tumors.
In
this
review,
we
provide
critical
analysis
on
homeostasis
dysregulation
development
progression
cancers.
Then
core
molecular
mechanisms
cuproptosis
discussed,
followed
summarizing
current
understanding
copper-based
agents
(copper
chelators,
ionophores,
complexes-based
dynamic
therapy)
treatment.
Additionally,
summarize
emerging
data
ionophores
to
subdue
chemotherapy
resistance
different
types
We
also
review
small-molecule
compounds
nanoparticles
(NPs)
that
kill
cells
inducing
cuproptosis,
which
will
shed
new
light
anticancer
drugs
through
future.
Finally,
important
concepts
pressing
questions
future
should
be
focused
were
discussed.
This
article
suggests
targeting
could
novel
antitumor
therapy
strategy
overcome
drug
resistance.
Antibiotics,
Journal Year:
2023,
Volume and Issue:
12(3), P. 524 - 524
Published: March 6, 2023
Background:
Since
disulfiram’s
discovery
in
the
1940s
and
its
FDA
approval
for
alcohol
use
disorder,
other
indications
have
been
investigated.
This
review
describes
potential
clinical
applications,
associated
risks,
challenges.
Methods:
For
this
narrative
review,
a
PubMed
search
was
conducted
articles
addressing
vivo
studies
of
disulfiram
with
an
emphasis
on
drug
repurposing
treatment
human
diseases.
The
key
terms
were
“disulfiram”
“Antabuse”.
Animal
vitro
highlighting
important
mechanisms
safety
issues
also
included.
Results:
In
total,
196
sources
our
research
focus
spanning
1948–2022
selected
inclusion.
addition
to
emerging
data
support
role
addictions
(e.g.,
cocaine),
infections
bacteria
such
as
Staphylococcus
aureus
Borrelia
burgdorferi,
viruses,
parasites),
inflammatory
conditions,
neurological
diseases,
cancers.
side
effects
range
from
minor
life-threatening,
lower
doses
conveying
less
risk.
Caution
is
needed
due
considerable
inter-subject
variability
pharmacokinetics.
Conclusions:
While
has
promise
“repurposed”
agent
disease,
risk
profile
concern.
well-controlled
trials
are
assess
efficacy
non-alcohol-related
indications.
ACS Nano,
Journal Year:
2023,
Volume and Issue:
17(11), P. 9972 - 9986
Published: May 18, 2023
Paraptosis
is
characterized
by
the
extensive
vacuolization
of
endoplasmic
reticulum
(ER)
and
mitochondria,
which
will
cause
release
damage-associated
molecular
patterns
to
promote
immunogenic
cell
death
(ICD).
However,
tumor
can
develop
an
immunosuppressive
microenvironment
affect
ICD
activation
for
purpose
immune
escape.
Herein,
a
paraptosis
inducer
(CMN)
constructed
amplify
effect
efficient
immunotherapy
inhibiting
activity
indoleamine
2,3-dioxygenase
(IDO).
Initially,
CMN
prepared
assembly
copper
ions
(Cu2+),
morusin
(MR),
IDO
inhibitor
(NLG919)
through
noncovalent
interactions.
Without
need
extra
drug
carriers,
possesses
very
high
contents
exhibits
favorable
GSH
responsiveness
disassembly.
Subsequently,
released
MR
trigger
ER
contributing
activating
immunotherapy.
Moreover,
NLG919
would
inhibit
remodel
cytotoxic
T
cells,
leading
intensive
antitumor
immunity.
Abundant
in
vivo
studies
indicate
that
superior
suppressing
proliferations
not
only
primary
but
also
metastatic
rechallenged
tumors.
Such
GSH-responsive
might
provide
promising
strategy
enhance
ACS Nano,
Journal Year:
2024,
Volume and Issue:
18(9), P. 6975 - 6989
Published: Feb. 20, 2024
Regarded
as
one
of
the
hallmarks
tumorigenesis
and
tumor
progression,
evasion
apoptotic
cell
death
would
also
account
for
treatment
resistance
or
failure
during
cancer
therapy.
In
this
study,
a
Ca2+/Cu2+
dual-ion
"nano
trap"
to
effectively
avoid
apoptosis
by
synchronously
inducing
paraptosis
together
with
was
successfully
designed
fabricated
breast
treatment.
brief,
disulfiram
(DSF)-loaded
amorphous
calcium
carbonate
nanoparticles
(NPs)
were
via
gas
diffusion
method.
Further
on,
Cu2+-tannic
acid
metal
phenolic
network
embedded
onto
NPs
surface
self-assembling,
followed
mDSPE-PEG/lipid
capping
form
DSF-loaded
dual-ions
trap".
The
as-prepared
nanotrap
undergo
acid-triggered
biodegradation
upon
being
endocytosed
cells
within
lysosome
Ca2+,
Cu2+,
DSF
releasing
simultaneously.
released
Ca2+
could
cause
mitochondrial
overload
lead
hydrogen
peroxide
(H2O2)
overexpression.
Meanwhile,
Ca2+/reactive
oxygen
species-associated
dysfunction
death.
Most
importantly,
be
further
induced
strengthened
toxic
dithiocarbamate
(DTC)–copper
complexes
formed
Cu2+
combined
DTC,
metabolic
products
DSF.
Additionally,
will
reduced
intracellular
glutathione
generate
Cu+,
which
can
catalyze
H2O2
produce
hydroxyl
radical
Cu+-mediated
Fenton-like
reaction
apoptosis.
Both
in
vitro
cellular
assays
vivo
antitumor
evaluations
confirmed
therapeutic
efficiency
dual
ion
nano
trap.
This
study
broaden
cognition
scope
dual-ion-mediated
multifunctional
nanoplatform.
